EXP-561,即4-苯基双环[2.2.2]辛-1-胺,是一种有机化合物,化学式为C14H19N。它可以被3-氯过氧苯甲酸氧化为1-硝基-4-苯基双环[2.2.2]辛烷。[1]在碳酸钾的存在下,它可以和1-溴-2-甲氧基乙烷在乙腈中加热反应,得到N-(2-甲氧基乙基)-4-苯基双环[2.2.2]辛-1-胺。[2]
1960年代,它被杜邦公司发展[3] 并被提名为一种抗抑郁药,不过失败了[4],也没有上市过。[5][6][7][8]
- ^ William Adcock, Gaik B. Kok. Polar substituent effects on fluorine-19 chemical shifts of aryl and vinyl fluorides: a fluorine-19 nuclear magnetic resonance study of some 1,1-difluoro-2-(4-substituted-bicyclo[2.2.2]oct-1-yl)ethenes. The Journal of Organic Chemistry. 1985-04, 50 (7): 1079–1087 [2021-05-18]. ISSN 0022-3263. doi:10.1021/jo00207a033 (英语).
- ^ Kick, Ellen K.; Smallheer, Joanne M.; Shaw, Scott A.; Vokits, Benjamin P.; Dilger, Andrew K.; Clark, Charles G.; Valente, Meriah Neissel; Jusuf, Sutjano; Wurtz, Nicholas R. Triazolopyridines as inhibitors of myeloperoxidase and/or eosinophil peroxidase and their preparation. 2017. WO 2017161145 A1.
- ^ US Patent 3308160 - PHENYLBICYCLO[Z.Z.Z]OCTANE-L-AMINES AND SALTS THEREOF
- ^ INTERNATIONAL REVIEW NEUROBIOLOGY, Volume 12 Page 160
- ^ Maj J, Skuza G, Sowińska H, Nowak G. Pharmacological properties of EXP 561, a potential antidepressant drug. Journal of Neural Transmission. 1987, 70 (1–2): 81–97. PMID 2822850. S2CID 23469131. doi:10.1007/BF01252511.
- ^ Lehmann HE, Ban TA, Debow SL. A clinical-pharmacological study with EXP 561. Current Therapeutic Research, Clinical and Experimental. June 1967, 9 (6): 306–8. PMID 4963065.
- ^ Gershon S, Hekimian LJ, Floyd A. Non-correlation of preclinical-clinical evaluation of a prosposed anti-depressant 4-phenyl-bicyclo(2,2,2)octan-1-amine hydrochloride monohydrate (EXP 561). Arzneimittel-Forschung. February 1968, 18 (2): 243–5. PMID 5695389.
- ^ Ross SB, Kelder D. Inhibition of 3H-dopamine accumulation in reserpinized and normal rat striatum. Acta Pharmacologica et Toxicologica. May 1979, 44 (5): 329–35. PMID 474143. doi:10.1111/j.1600-0773.1979.tb02339.x.